On July 29, Yinnuo Pharmaceutical announced that the Phase IB clinical trial of the company's self-developed ultra-long-acting GLP-1 receptor agonist esupaglutide α for adolescent obesity indications has completed its first patient enrollment in China. Currently, the company is carrying out a phase II clinical trial for obesity indications in Australia to explore a monthly dosage plan. Currently, no weight loss drugs for children and adolescents have been approved for marketing in our country.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.